NasdaqGS - Delayed Quote USD

Biogen Inc. (BIIB)

208.90 +6.44 (+3.18%)
At close: April 26 at 4:00 PM EDT
208.50 -0.40 (-0.19%)
After hours: April 26 at 7:51 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,663,100.00
9,835,600.00
10,173,400.00
10,981,700.00
13,444,600.00
Cost of Revenue
2,412,800.00
2,533,400.00
2,278,300.00
2,109,700.00
1,805,200.00
Gross Profit
7,250,300.00
7,302,200.00
7,895,100.00
8,872,000.00
11,639,400.00
Operating Expense
5,366,500.00
5,471,100.00
4,993,200.00
6,064,000.00
7,193,100.00
Operating Income
1,883,800.00
1,831,100.00
2,901,900.00
2,808,000.00
4,446,300.00
Net Non Operating Interest Income Expense
-40,600.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
Other Income Expense
-519,900.00
-563,900.00
847,200.00
-820,200.00
781,700.00
Pretax Income
1,323,300.00
1,296,800.00
3,591,800.00
1,745,200.00
5,047,500.00
Tax Provision
156,000.00
135,300.00
632,800.00
52,500.00
992,300.00
Earnings from Equity Interest Net of Tax
--
--
2,600.00
34,900.00
5,300.00
Net Income Common Stockholders
1,166,600.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Diluted NI Available to Com Stockholders
1,166,600.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Basic EPS
8.04
8.02
20.96
10.44
24.86
Diluted EPS
8.00
7.97
20.87
10.40
24.80
Basic Average Shares
144,900.00
144,700.00
145,300.00
149,100.00
160,900.00
Diluted Average Shares
145,775.00
145,600.00
146,000.00
149,600.00
161,300.00
Total Operating Income as Reported
--
--
--
2,840,700.00
4,550,100.00
Total Expenses
7,779,300.00
8,004,500.00
7,271,500.00
8,173,700.00
8,998,300.00
Net Income from Continuing & Discontinued Operation
1,166,600.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Normalized Income
1,619,917.82
1,663,218.40
2,340,484.80
2,346,262.00
3,375,223.60
Interest Income
213,000.00
276,500.00
89,300.00
11,000.00
42,000.00
Interest Expense
253,600.00
246,900.00
246,600.00
253,600.00
222,500.00
Net Interest Income
-40,600.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
EBIT
1,576,900.00
1,543,700.00
3,838,400.00
1,998,800.00
5,270,000.00
EBITDA
2,106,900.00
2,038,500.00
4,356,800.00
2,880,100.00
5,734,800.00
Reconciled Cost of Revenue
2,151,500.00
2,279,200.00
2,125,800.00
2,503,300.00
1,812,800.00
Reconciled Depreciation
530,000.00
494,800.00
518,400.00
487,700.00
457,200.00
Net Income from Continuing Operation Net Minority Interest
1,166,600.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Total Unusual Items Excluding Goodwill
-513,900.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Total Unusual Items
-513,900.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Normalized EBITDA
2,620,800.00
2,598,900.00
3,499,500.00
3,694,700.00
4,956,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-60,582.18
-58,281.60
150,884.80
-24,438.00
153,423.60
12/31/2020 - 9/17/1991

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

GILD Gilead Sciences, Inc.
65.42
+0.23%
 
BMY Bristol-Myers Squibb Company
44.85
+0.34%
 
MRK Merck & Co., Inc.
131.20
+0.37%
 
AZN AstraZeneca PLC
75.17
+0.19%
 
ABBV AbbVie Inc.
159.62
-4.58%
 
AMGN Amgen Inc.
269.98
+0.22%
 
LLY Eli Lilly and Company
733.51
+1.19%
 
PFE Pfizer Inc.
25.40
+0.55%
 
NVS Novartis AG
97.44
-1.64%
 
SNY Sanofi
49.13
-0.47%